<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>26671329</identifier>
<setSpec>1578-8865</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Alcántara Montero, A</dc:author>
<dc:description xml:lang="en">Overactive Bladder (OAB) is a common problem among men and women. Antimuscarinic drugs are a reference treatment for OAB and act by blocking the muscarinic receptors (M2 and M3 subtypes) in the bladder. Adherence to antimuscarinic treatment is usually low, due to the perceived lack of efficacy and adverse effects. Therefore, new treatments with different mechanisms of action and a more acceptable tolerability profile are needed, and that improve the symptoms of OAB. Mirabegron is a new treatment option for all patients with OAB and could solve an unmet need in patients still not satisfied, or where the antimuscarinic therapy is not indicated, is an alternative option for patients with OAB.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Vejiga hiperactiva</dc:subject>
<dc:subject>Mirabegrón</dc:subject>
<dc:subject>Agonistas beta-3 adrenérgicos</dc:subject>
<dc:subject>Overactive bladder</dc:subject>
<dc:subject>Beta 3 adreno-receptor agonists</dc:subject>
<dc:subject>Mirabegron</dc:subject>
<dc:date>2016 Nov - Dec </dc:date>
<dc:title xml:lang="es">Novedades en el tratamiento médico de la vejiga hiperactiva.</dc:title>
<dc:title xml:lang="en">[Developments in the medical treatment of overactive bladder].</dc:title>
<dc:publisher>Semergen</dc:publisher>
</metadata>
</record>
</pubmed-document>
